The KCTD9 Knockout NCI-H1975 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line. This loss-of-function model features targeted disruption of the KCTD9 gene, generating a heterogeneous knockout pool suitable for population-level analyses of the protein??s regulatory roles. Because the cells are polyclonal, they maintain a distribution of editing outcomes and provide a more physiologically representative system for studying gene function compared to single-clone isolates.
NCI-H1975 is an epithelial cell line established from the lung adenocarcinoma of a non-smoking female patient. These cells are a widely employed model for lung cancer research due to their well-characterized activating mutations in the epidermal growth factor receptor (EGFR) gene: L858R in exon 21 and T790M in exon 20. The T790M mutation is a gatekeeper alteration that confers resistance to first- and second-generation EGFR tyrosine kinase inhibitors, making this line particularly valuable for investigating acquired drug resistance and testing next-generation therapeutics.
KCTD9 encodes a potassium channel tetramerization domain-containing protein that functions as a critical adaptor and negative regulator at the intersection of innate immunity, inflammation, and developmental signaling. Mechanistically, it dampens Toll-like receptor (TLR)-mediated NF-??B activation by binding to TRAF6 and inhibiting its auto-ubiquitination, thereby limiting downstream IKK and NF-??B activity. Simultaneously, KCTD9 promotes the ubiquitination and proteasomal degradation of ??-catenin, suppressing canonical Wnt/??-catenin signaling and reducing TCF/LEF-dependent transcription. In addition, the protein interacts with NLRP3 and the Cullin3 ubiquitin ligase complex to restrain NLRP3 inflammasome assembly, preventing Caspase-1 activation and IL-1?? maturation. Upstream, KCTD9 expression is induced by TLR ligands, IL-1??, TNF-??, and type I interferons, establishing feedback loops that fine-tune immune responses.
In the context of EGFR-mutant NCI-H1975 cells, KCTD9 disruption may unmask pro-inflammatory and pro-survival pathways that are normally under restraint. Loss of KCTD9-mediated inhibition can lead to heightened TRAF6-dependent NF-??B signaling, stabilization of ??-catenin and subsequent Wnt target gene transcription, and possibly enhanced inflammasome activity. These molecular shifts are directly relevant to understanding how inflammatory signals modulate drug resistance, tumor progression, and immune evasion in lung adenocarcinoma. The model thus enables dissection of the crosstalk between oncogenic EGFR signaling and the TLR/NF-??B, Wnt/??-catenin, and NLRP3 inflammasome pathways.
This polyclonal knockout cell population is suited for a broad range of investigational applications, including western blotting and RT-qPCR to confirm KCTD9 disruption and quantify downstream target expression (e.g., NF-??B and Wnt-responsive genes). Researchers can perform co-immunoprecipitation assays to map altered interactions between TRAF6, ??-catenin, and NLRP3, or use NF-??B and Wnt/??-catenin luciferase reporters to measure pathway activity. Additional analyses such as phospho-signaling profiling, flow cytometry for immune cell markers, inflammasome activation assays, and drug sensitivity testing facilitate comprehensive studies of innate immune regulation in lung cancer. For further details or custom product inquiries, please contact Ascent Research.
